BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37549269)

  • 1. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
    Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C
    Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.
    Li M; Liu M; Han W; Wang Z; Han D; Patalano S; Macoska JA; Balk SP; He HH; Corey E; Gao S; Cai C
    Cancer Res; 2023 May; 83(10):1684-1698. PubMed ID: 36877164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.
    Gao S; Chen S; Han D; Wang Z; Li M; Han W; Besschetnova A; Liu M; Zhou F; Barrett D; Luong MP; Owiredu J; Liang Y; Ahmed M; Petricca J; Patalano S; Macoska JA; Corey E; Chen S; Balk SP; He HH; Cai C
    Nat Genet; 2020 Oct; 52(10):1011-1017. PubMed ID: 32868907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioneer of prostate cancer: past, present and the future of FOXA1.
    Teng M; Zhou S; Cai C; Lupien M; He HH
    Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
    Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
    Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
    Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
    Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.
    Hankey W; Chen Z; Wang Q
    Cancer Res; 2020 Jun; 80(12):2427-2436. PubMed ID: 32094298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity.
    Cai C; He HH; Gao S; Chen S; Yu Z; Gao Y; Chen S; Chen MW; Zhang J; Ahmed M; Wang Y; Metzger E; Schüle R; Liu XS; Brown M; Balk SP
    Cell Rep; 2014 Dec; 9(5):1618-1627. PubMed ID: 25482560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.
    Mukhopadhyay NK; Kim J; You S; Morello M; Hager MH; Huang WC; Ramachandran A; Yang J; Cinar B; Rubin MA; Adam RM; Oesterreich S; Di Vizio D; Freeman MR
    Oncogene; 2014 Jun; 33(25):3235-45. PubMed ID: 23893242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
    Jin HJ; Zhao JC; Wu L; Kim J; Yu J
    Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CACUL1 functions as a negative regulator of androgen receptor in prostate cancer cells.
    Choi H; Lee SH; Um SJ; Kim EJ
    Cancer Lett; 2016 Jul; 376(2):360-6. PubMed ID: 27085459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoform-Specific Lysine Methylation of RORα2 by SETD7 Is Required for Association of the TIP60 Coactivator Complex in Prostate Cancer Progression.
    Song H; Chu JW; Park SC; Im H; Park IG; Kim H; Lee JM
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32120841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation.
    Zhang X; Tanaka K; Yan J; Li J; Peng D; Jiang Y; Yang Z; Barton MC; Wen H; Shi X
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17284-9. PubMed ID: 24101509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.
    Lupien M; Eeckhoute J; Meyer CA; Wang Q; Zhang Y; Li W; Carroll JS; Liu XS; Brown M
    Cell; 2008 Mar; 132(6):958-70. PubMed ID: 18358809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression.
    Besschetnova A; Han W; Liu M; Gao Y; Li M; Wang Z; Labaf M; Patalano S; Venkataramani K; Muriph RE; Macoska JA; Siegfried KR; Evans J; Balk SP; Gao S; Han D; Cai C
    Cancer Res Commun; 2023 Aug; 3(8):1716-1730. PubMed ID: 37663929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.
    Zhao Y; Tindall DJ; Huang H
    Int J Biol Sci; 2014; 10(6):614-9. PubMed ID: 24948874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription.
    Metzger E; Wissmann M; Yin N; Müller JM; Schneider R; Peters AH; Günther T; Buettner R; Schüle R
    Nature; 2005 Sep; 437(7057):436-9. PubMed ID: 16079795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
    Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
    Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.